• Linda Shore-Lesserson, Carol Bodian, Frances Vela-Cantos, George Silvay, and David L Reich.
• Department of Anesthesiology, Mt. Sinai Medical Center, One Gustave L. Levy Place, Box 1010, New York, NY, USA. linda.shore@msnyuhealth.org
• J. Cardiothorac. Vasc. Anesth. 2005 Aug 1; 19 (4): 453-8.

ObjectivesThe purpose of this study was to determine the potential benefit of antifibrinolytic (AF) therapy in improving hemostasis in descending aortic surgery in which extracorporeal distal perfusion is used.DesignRetrospective database study.SettingUniversity hospital.ParticipantsSeventy-two patients who underwent descending thoracic or thoracoabdominal aortic replacement during the period from January 1993 through December 1996 when the use of AF therapy was emerging.InterventionsNone.Measurements And Main ResultsSeventy-two records met criteria for inclusion. The use of AF therapy had no significant effect on any bleeding or transfusion outcome in any model. Excessive chest tube drainage postoperatively was independently associated with repeat surgery and intraoperative hypothermia. The risk of receiving a red blood cell (RBC) transfusion was independently predicted by low preoperative hemoglobin and age > or =65 years. Cross-clamp was an independent predictor of receiving a transfusion of non-RBC products (p = 0.03).ConclusionsThe authors could not show a beneficial effect of AF therapy on bleeding and transfusion, although current practice shows that this therapy continues to be used. Because heterogeneity of patient population exists and bias cannot be completely excluded, a prospective investigation evaluating efficacy and safety in this population is warranted.

23 keywords...

hide…